Who asks about tesamorelin and what they want to understand
Tesamorelin searches usually start with one of two questions: what is it, and is it the same as the brand drug Egrifta.
TL;DR
- Tesamorelin is a GHRH analog — a synthetic molecule that mimics the hormone that triggers growth hormone release.
- It is FDA-approved only as the brand drug Egrifta, to reduce excess abdominal fat in adults with HIV and lipodystrophy. Other uses are not approved and not established.
- People searching for it have often read about it in connection with belly fat. That use outside HIV is not approved.
What tesamorelin is
Tesamorelin is a synthetic GHRH analog. GHRH (growth hormone releasing hormone — the body's natural signal to the pituitary to release GH) degrades quickly in the bloodstream. Tesamorelin is a stabilized version designed to last longer and act more consistently.
FDA approved it in 2010 under the brand name Egrifta to reduce excess abdominal fat in adults with HIV-associated lipodystrophy (in plain English: the abnormal fat redistribution that occurs in some people on HIV treatment). That approval is based on multiple controlled clinical trials (FDA label, 2010).
Compounded tesamorelin is not FDA-approved, and it is not the same as Egrifta.
How it works
Think of the growth hormone axis like a two-step relay race. The hypothalamus fires the starting gun with GHRH. The pituitary runs the next leg and releases GH. Tesamorelin is a synthetic starter pistol: it fires the same signal as the body's own GHRH, and the pituitary releases GH in response.
Who asks about tesamorelin
People come to this topic from two directions. Some are adults — often men between 40 and 60 — who have read about the clinical trials that showed reductions in visceral fat. Those trials studied adults with HIV and lipodystrophy; use outside that group is not approved and not established. Others encounter the name while researching HIV medications and want to understand whether it has any application outside that context.
The common thread is visceral fat (the fat that sits deep inside the abdomen, around the organs), which many people find hard to shift.
What the research says
Published randomized controlled trials in HIV-positive adults showed significant reductions in visceral adipose tissue with tesamorelin compared with placebo (Falutz et al., Journal of Clinical Endocrinology & Metabolism, 2010). In adults without HIV, studies are small, and no benefit for visceral fat has been established.
What is approved and what is not
Egrifta is approved for one use: reducing excess abdominal fat in adults with HIV and lipodystrophy. Other uses are not approved and not established. Compounded versions are not FDA-approved. Common side effects in the trials included edema and joint discomfort in some participants.
The Halftime POV
Tesamorelin has stronger trial evidence than most compounds in this space, but that evidence is for one group: adults with HIV and lipodystrophy. Search results often blur that line. We keep it sharp: the approved use is narrow, and other uses are not established.
Related reading:
- Tesamorelin: from HIV lipodystrophy to visceral fat research
- Who asks about CJC-1295
- Sarcopenia prevention for men over 50
- The growth hormone axis explained
- Fatigue in men over 40: a hormonal map
FAQ
Q: What is tesamorelin used for? A: Tesamorelin is a GHRH analog (in plain English: a synthetic version of the hormone that tells the pituitary to release growth hormone). It is FDA-approved only as the brand drug Egrifta, to reduce excess abdominal fat in adults with HIV and lipodystrophy. Other uses, including visceral fat in adults without HIV, are not approved and not established. Compounded tesamorelin is not FDA-approved.
Q: Who asks about tesamorelin? A: People who search for tesamorelin are often adults — frequently men in their late thirties to fifties — who have read about it in connection with visceral belly fat. Its approved use is much narrower: adults with HIV and lipodystrophy.
Q: Is tesamorelin the same as Egrifta? A: No. Egrifta is the FDA-approved brand drug. Compounded tesamorelin is a different product. FDA has not approved it, and it is not the same as Egrifta.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved.
Sources
- Falutz J et al. — Effects of tesamorelin in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials — J Clin Endocrinol Metab, 2010
- Egrifta FDA label, 2010
Frequently asked questions
what is tesamorelin used for
Tesamorelin is a GHRH analog (in plain English: a synthetic version of the hormone that tells the pituitary to release growth hormone). It is FDA-approved only as the brand drug Egrifta, to reduce excess abdominal fat in adults with HIV and lipodystrophy. Other uses, including visceral fat in adults without HIV, are not approved and not established. Compounded tesamorelin is not FDA-approved.
who asks about tesamorelin
People who search for tesamorelin are often adults — frequently men in their late thirties to fifties — who have read about it in connection with visceral belly fat. Its approved use is much narrower: adults with HIV and lipodystrophy.
is tesamorelin the same as Egrifta
No. Egrifta is the FDA-approved brand drug. Compounded tesamorelin is a different product. FDA has not approved it, and it is not the same as Egrifta.
